The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series

To describe the clinical presentation of MOG antibody disease (MOG-AD) in a series of patients at a single academic center. We performed a retrospective review of patients with MOG antibodies. We review the clinical presentation of 11 patients with MOG antibodies. In patients seen at Duke University Health System with MOG antibodies, the most common presentation was optic neuritis. Rituximab was the most used treatment for long-term management. Our case series highlights the common presentation of MOG antibody disease (MOG-AD) at a single academic medical center. •The most common presentation of MOG antibody disease in adults at our acedemic center is optic neuritis followed by transverse myelitis.•At Duke University Medical Center, the most common presentation of MOG antibody disease (MOG-AD) in an adult population is optic neuritis, followed by transverse myelitis.•Patients who presented acutelywith symptoms concerning for MOG-AD were treated with high dose IV steroids, followed by an oral steroid taper.•There is limited data to support a specific long term disease modifying treatment for MOG-AD.; however, rituximab was the most commonly used treatment.